Stockreport

Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference [Yahoo! Finance]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF billion , forecasting growth driven by its Cabometyx renal cell carcinoma (RCC) franchise and the recent neuroendocrine tumor (NET) launch, which the company sees as an [Read more]